Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47) 47
female (39) 39
male (38) 38
middle aged (37) 37
adult (34) 34
index medicus (33) 33
adolescent (24) 24
treatment outcome (22) 22
analysis (20) 20
hematology (17) 17
rheumatology (17) 17
young adult (15) 15
aged (14) 14
oncology (13) 13
pediatrics (13) 13
risk factors (13) 13
care and treatment (12) 12
prognosis (12) 12
life sciences (11) 11
remission induction (11) 11
child (10) 10
retrospective studies (10) 10
animals (9) 9
chemotherapy (9) 9
disease-free survival (9) 9
immunology (9) 9
child, preschool (8) 8
double-blind method (8) 8
research (8) 8
survival analysis (8) 8
acute lymphoblastic leukemia (7) 7
acute lymphocytic-leukemia (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
arthritis (7) 7
immunology and allergy (7) 7
physics, condensed matter (7) 7
poster presentation (7) 7
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (7) 7
therapy (7) 7
time factors (7) 7
abridged index medicus (6) 6
cancer (6) 6
children (6) 6
drug therapy (6) 6
health aspects (6) 6
materials science (6) 6
medicine, general & internal (6) 6
multivariate analysis (6) 6
patients (6) 6
pediatrics, perinatology, and child health (6) 6
precursor cell lymphoblastic leukemia-lymphoma - diagnosis (6) 6
precursor cell lymphoblastic leukemia-lymphoma - mortality (6) 6
prospective studies (6) 6
adults (5) 5
aged, 80 and over (5) 5
antibodies, monoclonal - adverse effects (5) 5
antibodies, monoclonal - therapeutic use (5) 5
darifenacin (5) 5
dermatology (5) 5
diagnosis (5) 5
drugs (5) 5
efficacy (5) 5
follow-up studies (5) 5
immunophenotyping (5) 5
philadelphia chromosome (5) 5
prognostic factors (5) 5
survival (5) 5
transplantation, homologous (5) 5
usage (5) 5
acute lymphocytic leukemia (4) 4
adolescents (4) 4
age factors (4) 4
anakinra (4) 4
bibliography (4) 4
chemistry (4) 4
chemistry, physical (4) 4
clinical trial (4) 4
clinical trials (4) 4
critical care medicine (4) 4
diseases of the musculoskeletal system (4) 4
expression (4) 4
follow-up (4) 4
food science & technology (4) 4
france (4) 4
hematopoietic stem cell transplantation (4) 4
intensive care units (4) 4
interleukin-1beta - antagonists & inhibitors (4) 4
juvenile arthritis (4) 4
k ei chemistry, physical (4) 4
materials science, multidisciplinary (4) 4
medical research (4) 4
medicine (4) 4
pharmaceutical industry (4) 4
polymers (4) 4
population (4) 4
precursor cell lymphoblastic leukemia-lymphoma - genetics (4) 4
precursor cell lymphoblastic leukemia-lymphoma - pathology (4) 4
precursor cell lymphoblastic leukemia-lymphoma - therapy (4) 4
prevalence (4) 4
recurrence (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
by Ruperto, Nicolino and Brunner, Hermine I and Quartier, Pierre and Constantin, Tamás and Wulffraat, Nico and Horneff, Gerd and Brik, Riva and McCann, Liza and Kasapcopur, Ozgur and Rutkowska-Sak, Lidia and Schneider, Rayfel and Berkun, Yackov and Calvo, Inmaculada and Erguven, Muferet and Goffin, Laurence and Hofer, Michael and Kallinich, Tilmann and Oliveira, Sheila K and Uziel, Yosef and Viola, Stefania and Nistala, Kiran and Wouters, Carine and Cimaz, Rolando and Ferrandiz, Manuel A and Flato, Berit and Gamir, Maria Luz and Kone-Paut, Isabelle and Grom, Alexei and Magnusson, Bo and Ozen, Seza and Sztajnbok, Flavio and Lheritier, Karine and Abrams, Ken and Kim, Dennis and Martini, Alberto and Lovell, Daniel J and PRCSG and PRINTO
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 25, pp. 2396 - 2406
In two placebo-controlled trials, canakinumab, an anti-interleukin-1β monoclonal antibody, achieved a response, prevented flares, and allowed glucocorticoid... 
RHEUMATOID-ARTHRITIS | CRITERIA | MEDICINE, GENERAL & INTERNAL | RECEPTOR ANTAGONIST ANAKINRA | EFFICACY | DOUBLE-BLIND | PRELIMINARY DEFINITION | FOLLOW-UP | CLASSIFICATION | SELECT CATEGORIES | CHILDREN | Glucocorticoids - therapeutic use | Double-Blind Method | Humans | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Male | Thrombocytopenia - chemically induced | Methotrexate - therapeutic use | Infection - chemically induced | Arthritis, Juvenile - drug therapy | Macrophage Activation Syndrome - etiology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Adolescent | Arthritis, Juvenile - complications | Female | Drug Therapy, Combination | Neutropenia - chemically induced | Child | Interleukin-1beta - antagonists & inhibitors | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Juvenile arthritis | Pediatrics | Cytokines | Fever | Rheumatology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
by F. De Benedetti and J. Anton and M. Gattorno and H. Lachmann and I. Kone-Paut and S. Ozen and J. Frenkel and A. Simon and A. Zeft and E. Ben-Chetrit and H. M. Hoffman and Y. Joubert and K. Lheritier and A. Speziale and J. Guido and Roberta Caorsi and Federica Penco and Alice Grossi and Antonella Insalaco and Maria Alessio and Giovanni Conti and Federico Marchetti and Alberto Tommasini and Silvana Martino and Romina Gallizzi and Annalisa Salis and Francesca Schena and Francesco Caroli and Alberto Martini and Gianluca Damonte and Isabella Ceccherini and Marco Gattorno and Marie-Louise Frémond and Carolina Uggenti and Lien Van Eyck and Isabelle Melki and Darragh Duffy and Vincent Bondet and Yoann Rose and Bénédicte Neven and Yanick Crow and Mathieu P. Rodero and Yvonne Kusche and Johannes Roth and Katarzyna Barczyk-Kahlert and Giovanna Ferrara and Annalisa Chiocchetti and Silvio Polizzi and Josef Vuch and Diego Vozzi and Anna Mondino and Erica Valencic and Serena Pastore and Andrea Taddio and Flavio Faletra and Umberto Dianzani and Ugo Ramenghi and Alberto Tommasini and Qing Zhou and Xiaomin Yu and Erkan Demirkaya and Natalie Deuitch and Deborah Stone and Wanxia Tsai and Amanda Ombrello and Tina Romeo and Elaine F. Remmers and JaeJin Chae and Massimo Gadina and Steven Welch and Seza Ozen and Rezan Topaloglu and Mario Abinun and Daniel L. Kastner and Ivona Aksentijevich and Donatella Vairo and Rosalba Monica Ferraro and Giulia Zani and Jessica Galli and Micaela De Simone and Marco Cattalini and Elisa Fazzi and Silvia Giliani and Ebun Omoyinmi and Ariane Standing and Dorota Rowczenio and Annette Keylock and Sonia Melo Gomes and Fiona Price-Kuehne and Sira Nanthapisal and Claire Murphy and Thomas Cullup and Lucy Jenkins and Kimberly Gilmour and Despina Eleftheriou and Helen Lachmann and Philip Hawkins and Nigel Klein and Paul Brogan and Anita Dhanrajani and ...
Pediatric Rheumatology Online Journal, 05/2017, Volume 15, Issue S1, pp. 1 - 104
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three
by Riccardo Papa and Alessandro Consolaro and Francesca Minoia and Roberta Caorsi and Gianmichele Magnano and Marco Gattorno and Angelo Ravelli and Paolo Picco and Roberto Pillon and Denise Pires Marafon and Lidia Meli and Claudia Bracaglia and Andrea Taddio and Fabrizio De Benedetti and Enes Turan and Sara Sebnem Kilic and Yasuhiko Itoh and Tomoko Shigemori and Shingo Yamanishi and Hidehiko Nagasaki and Ela Tarakci and Nilay Arman and Devrim Tarakci and Yusuf S. Akgul and Ozgur Kasapcopur and Emily Wilson and Hanna Lythgoe and Eve Smith and Jenny Preston and Michael W. Beresford and Lynn R. Spiegel and Jennifer Stinson and Mark Connelly and Adam Huber and Nadia Luca and Argerie Tsimicalis and Stephanie Luca and Naweed Tajuddin and Roberta Berard and Julie Barsalou and Sarah Campillo and Brian Feldman and Shirley Tse and Paul Dancey and Ciaran Duffy and Nicole Johnson and Patrick McGrath and Natalie Shiff and Lori Tucker and Charles Victor and Lynn R. Spiegel and Chitra Lalloo and Lauren Harris and Joseph Cafazzo and Lori Tucker and Kristin Houghton and Brian Feldman and Nadia Luca and Ronald Laxer and Jennifer Stinson and Nilay Arman and Ela Tarakci and Ozgur Kasapcopur and Madeleine Rooney and Roisin Campbell and Catherine Wright and Wineke Armbrust and Otto Lelieveld and Jolanda Tuinstra and Nico Wulffraat and Joyce Bos and Jeanette Cappon and Marion van Rossum and Mariët Hagedoorn and Anna Vermé and Ylva Lampela and Ayse Huri Ozdogan and S. Ugurlu and K. Barut and A. Androvic and O. Kasapçopu and Emily Wilson and Jody Etheridge and Eve Smith and Katie Dobson and Sue Kemp and Michael W. Beresford and AnnaCarin Horne and Karin Palmblad and Malin Höglund and Natalia Stepanenko and Svetlana Salugina and Evgeny Fedorov and Irina Nikishina and Maria Kaleda and Nilay Arman and Ela Tarakci and Kenan Barut and Amra Adrovic and Sezgin Sahin and ...
Pediatric Rheumatology Online Journal, 05/2017, Volume 15, Issue S1, pp. 203 - 259
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text THU0215 Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial
by Ruperto, N and Brunner, H.I and Quartier, P and Constantin, T and Alexeeva, E and Schneider, R and Kone-Paut, I and Schikler, K and Marzan, K and Wulffraat, N and Padeh, S and Chasnyk, V and Wouters, C and Kuemmerle-Deschner, J.B and Kallinich, T and Lauwerys, B and Haddad, E and Nasonov, E and Trachana, M and Vougiouka, O and Leon, K and Speziale, A and Lheritier, K and Martini, A and Lovell, D and on behalf of PRINTO/PRCSG
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue Suppl 2, pp. 265 - 266
BackgroundSJIA is a distinct and debilitating form of arthritis associated with elevated cytokine (interleukin [IL]-1 and IL-6) levels.1 Studies have shown... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients
by Quartier, P and Grom, A and Ruperto, N and Brunner, H and Schikler, K and Erguven, M and Goffin, L and Hofer, M and Kallinich, T and Marzan, K and Gaillez, C and Lheritier, K and Abrams, K and Martini, A and Lovell, D
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue Suppl 2, pp. 132 - 132
Background Canakinumab (CAN), a selective, fully-human anti-IL-1β monoclonal antibody is approved for SJIA in over 30 countries. Efficacy and safety of CAN... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text FRI0496 Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis with and Without Fever
by Ruperto, N and Brunner, H and Quartier, P and Constantin, T and Alexeeva, E and Kone-Paut, I and Marzan, K and Wulffraat, N and Schneider, R and Padeh, S and Chasnyk, V and Wouters, C and Kummerle Deschner, J and Kallinich, T and Lauwerys, B and Haddad, E and Nasonov, E and Trachana, M and Vougiouka, O and Abrams, K and Leon, K and Lheritier, K and Martini, A and Lovell, D
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2015, Volume 74, Issue Suppl 2, pp. 608 - 608
BackgroundCanakinumab (CAN) leads to improvement for patients (pts) with systemic juvenile idiopathic arthritis (SJIA)1. However, little is known about... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text THU0579 Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial
by Ruperto, N and Brunner, H.I and Quartier, P and Constantin, T and Alexeeva, E and Kone-Paut, I and Marzan, K and Wulffraat, N and Schneider, R and Padeh, S and Chasnyk, V and Wouters, C and Kuemmerle-Deschner, J.B and Kallinich, T and Lauwerys, B and Haddad, E and Nasonov, E and Trachana, M and Vougiouka, O and Leon, K and Speziale, A and Lheritier, K and Martini, A and Lovell, D
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue Suppl 2, pp. 401 - 402
BackgroundThe main therapeutic goals that can determine success of biologic treatment in systemic juvenile idiopathic arthritis (SJIA) include achieving and... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text THU0502 Efficacy and safety of canakinumab in patients with still's disease: a pooled analysis of sjia data by age groups
by Feist, E and Quartier, P and Fautrel, B and Schneider, R and Sfriso, P and Efthimiou, P and Cantarini, L and Lheritier, K and Leon, K and Karyekar, C and Speziale, A
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue Suppl 2, p. 395
BackgroundStill's disease presents in paediatric and adult patients (pts) as a disease continuum with similar symptoms and pathophysiology.1,2ObjectivesTo... 
Adolescence | Immunogenicity | Interleukin 1 | Monoclonal antibodies | Data processing | Juvenile rheumatoid arthritis | Arthritis | Adults | Teenagers | Children | Safety | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
by Grom, Alexei A and Ilowite, Norman T and Pascual, Virginia and Brunner, Hermine I and Martini, Alberto and Lovell, Daniel and Ruperto, Nicolino and Leon, Karolynn and Lheritier, Karine and Abrams, Ken and Cuttica, Ruben and Emminger, Wolfgang and Goffin, Laurence and Joos, Rik and Lauwerys, Bernard and Wouters, Carine and Hilário, Maria Odete Esteves and de Oliveira, Sheila Knupp Feitosa and Len, Claudio and Radominski, Sebastiao and Sztajnbok, Flavio Roberto and Haddad, Elie and Hofer, Michael and Houghton, Kristin and Huber, Adam and Saurenmann, Traudel and Schneider, Rayfel and Tucker, Lori and Bader‐Meunier, Brigitte and Desjonqueres, Marine and Fischbach, Michel and Kone‐Paut, Isabelle and Marie, Isabelle and Mogenet, Agnes and Mouy, Richard and Quartier, Pierre and Berner, Reinhard and Foeldvari, Ivan and Foell, Dirk and Frosch, Michael and Haas, Johannes‐Peter and Horneff, Gerd and Hufnagel, Markus and Kallinich, Tilmann and Kuemmerle‐Deschner, Jasmin and Lehmann, Hartwig and Lutz, Thomas and Thon, Angelika and Trauzeddel, Ralf and Tzaribachev, Nikolay and Weibarth‐Riedel, Elisabeth and Chrousos, Georgios and Trachana, Maria and Vougiouka, Olga and Constantin, Tamas and Barash, Judith and Berkun, Yackov and Brik, Riva and Harel, Liora and Nahum, Amit and Pade, Shay and Uziel, Yosef and Alessio, Maria and Cimaz, Rolando and Corona, Fabrizia and Gerloni, Valeria and Wulffraat, N. M and Ferrandiz, Manuel and Rutkowska‐Sak, Lidia and Alekseeva, Ekaterina and Chasnyk, Vyacheslav and Nasonov, Evgeny and Stanislav, Marina and Anton, Jordi and Calvo, Inmaculada and Gamir, Mari Luz and Robledillos, Juan Carlos and Magnusson, Bo and Erguven, Muferet and Kasapcopur, Ozgur and Ozdogan, Huri and Ozen, Seza and Unsal, Erbil and Chieng, Alice and Foster, Helen and McCann, Liza and Ramanan, Athimalaip and Southwood, Taunton and Wilkinson, Nicholas and Woo, Patricia and Higgins, Gloria Christine and Kingsbury, Daniel and Lopez‐Benitez, Jorge and Marzan, Katherine and Morris, Paula and Natter, Marc and Schikler, Kenneth Noel and Pediat Rheumatology Collaborative and Paediat Rheumatology Int Trials Or and Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group
Arthritis & Rheumatology, ISSN 2326-5191, 01/2016, Volume 68, Issue 1, pp. 218 - 228
Objective In pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis (JIA), but reported adverse... 
PATHOGENESIS | OF-RHEUMATOLOGY RECOMMENDATIONS | DIAGNOSTIC-SIGNIFICANCE | INTERFERON-GAMMA | MEDICAL THERAPY | INTERLEUKIN-1 RECEPTOR ANTAGONIST | 2013 UPDATE | DOUBLE-BLIND | ANAKINRA | RHEUMATOLOGY | CHILDREN | Humans | Risk Factors | Antibodies, Monoclonal - adverse effects | Macrophage Activation Syndrome - chemically induced | Child, Preschool | Male | Arthritis, Juvenile - drug therapy | Young Adult | Infection - epidemiology | Adolescent | Macrophage Activation Syndrome - epidemiology | Female | Child | Antirheumatic Agents - therapeutic use | Databases, Factual | Confidence intervals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients
by Wulffraat, N.M and Ruperto, N and Brunner, H.I and Oliveira, S and Uziel, Y and Nistala, K and Cimaz, R and Ferrandiz, M.A and Flato, B and Gamir, M.L and Koné-Paut, I and Gaillez, C and Lheritier, K and Abrams, K and Martini, A and Lovell, D.J
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue Suppl 2, pp. 130 - 130
Background Systemic juvenile idiopathic arthritis (SJIA) is characterized by recurrent flares of active disease comprising of fever, arthritis and markedly... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
by Quartier, P and Grom, A and Ruperto, N and Brunner, HI and Schikler, K and Erguven, M and Goffin, L and Hofer, M and Kallinich, T and Marzan, K and Gaillez, C and Lheritier, K and Abrams, K and Martini, A and Lovell, DJ
Pediatric Rheumatology, ISSN 1546-0096, 09/2014, Volume 12, Issue S1, pp. P66 - P66
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text THU0477 Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients
by Quartier, P and Ruperto, N and Wulffrat, N and Brunner, H and Brik, R and McCann, L and Foster, H and Frosch, M and Gerloni, V and Harel, L and Len, C and Houghton, K and Joos, R and Kim, D and Abrams, K and Lheritier, K and Ricci, J and Martini, A and Lovell, D
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2013, Volume 72, Issue Suppl 3, pp. A325 - A326
Background Efficacy and safety of canakinumab (CAN), a selective, fully human, anti-interleukin-1β monoclonal antibody, in SJIA is supported by the results of... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text FRI0528 Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome
by Grom, A.A and Brunner, H.I and Ruperto, N and Martini, A and Lovell, D and Pascual, V and Lheritier, K and Abrams, K and Ilowite, N
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue Suppl 2, pp. 578 - 578
Background Canakinumab is a fully human, selective, anti-IL-1β monoclonal antibody approved for the treatment of patients with systemic juvenile idiopathic... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text AB1186 IL-1beta inhibition with canakinumab in patients with systemic juvenile idiopathic arthritis: Efficacy and safety outcomes from a single-dose, placebo-controlled study
by Quartier, P and Erguven, M and Horneff, G and Berkun, Y and Lheritier, K and Kim, D and Abrams, K and Constantin, T
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2013, Volume 71, Issue Suppl 3, pp. 705 - 705
Background IL-1β, a key inflammatory cytokine, appears to play a prominent role in systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a fully... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text AB1185 Sustained maintenance of adapted ACR pediatric response with canakinumab in patients with active systemic juvenile idiopathic arthritis
by Quartier, P and Anton, J and Barash, J and Berner, R and Abrams, K and Lheritier, K and Kim, D and Wulffraat, N
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2013, Volume 71, Issue Suppl 3, pp. 705 - 705
Background Systemic juvenile idiopathic arthritis (SJIA) is a rare autoinflammatory disease. Phase 3 data showed canakinumab (CAN), a fully human selective... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text AB1182 Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis
by Ruperto, N and Brunner, H and Quartier, P and Constantin, T and Wulffraat, N and Horneff, G and Brik, R and McCann, L and Kasapcopur, O and Rutkowska-Sak, L and Schneider, R and Berkun, Y and Calvo, I and Erguven, M and Goffin, L and Hofer, M and Kallinich, T and Knupp, S and Uziel, Y and Viola, S and Nistala, K and Wouters, C and Cimaz, R and Ferrandiz, M and Flato, B and Luz Gamir, M and Kone-Paut, I and Grom, A and Magnusson, B and Ozen, S and Sztajnbok, F and Lheritier, K and Kim, D and Abrams, K and Martini, A and Lovell, D
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2013, Volume 71, Issue Suppl 3, pp. 705 - 705
Background Systemic juvenile idiopathic arthritis (SJIA) is an IL1β-mediated autoinflammatory disease, characterized by spiking intermittent fever, rash, and... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
by Koné-Paut, Isabelle and Lachmann, Helen J and Kuemmerle-Deschner, Jasmin B and Hachulla, Eric and Leslie, Kieron S and Mouy, Richard and Ferreira, Alberto and Lheritier, Karine and Patel, Neha and Preiss, Ralph and Hawkins, Philip N and Canakinumab in CAPS Study Group, in CAPS Study Group and Canakinumab CAPS Study Grp and Canakinumab in CAPS Study Group and on behalf of the Canakinumab in CAPS Study Group
Arthritis research & therapy, ISSN 1478-6354, 2011, Volume 13, Issue 6, pp. R202 - R202
Introduction: To assess the effect of canakinumab, a fully human anti-interleukin-1 beta antibody, on symptoms and health-related quality of life (HRQoL) in... 
AUTOINFLAMMATORY DISEASES | RHEUMATOLOGY | ARTHRITIS | INTERLEUKIN-1-BETA | FATIGUE | SF-36 | Humans | Middle Aged | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Male | Young Adult | Cryopyrin-Associated Periodic Syndromes - blood | C-Reactive Protein - metabolism | Interleukin-6 - blood | Adult | Female | Surveys and Questionnaires | Cryopyrin-Associated Periodic Syndromes - pathology | Child | Interleukin-1beta - antagonists & inhibitors | Serum Amyloid A Protein - metabolism | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Cryopyrin-Associated Periodic Syndromes - drug therapy | Remission Induction | Adolescent | Quality of Life | Aged | Health Status
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18.